Purecell GroupPartnership
AAGH partners with Purecell Group, one of the most outstanding anti-aging medicine institutions throughout the world in Australia. Founded in 2012, Purecell Group is dedicated to revolutionary cell regenerative and anti-aging medicine technologies.
Caringbah, NSW
Australia
About Purecell Group
A group of internationally recognized and prestigious authoritative scientists dedicated to the development and clinical trials of advanced technologies in cell regenerative and anti-aging medicine.
Leading Research
Collaborates with CalTech and leading research facilities worldwide to advance regenerative medicine standards.
TGA Approved
Most authoritative legal commercial application organization for stem cell therapy and anti-aging in Australia.
Global Leadership
Clear global leader in advanced stem cell therapy research and safe clinical applications with international collaborations.
Revolutionary UCF Cytokines Technology
Purecell Group has achieved three major technological breakthroughs with their UCF cytokines patent technology, valued at 150 million CNY, establishing new standards in regenerative medicine worldwide.
Led by Professor Andrew French, one of the world's top five human embryonic stem cell clones, Purecell represents the pinnacle of cell regenerative medicine research and development.
UCF Cytokines Patent Technology
Three major technological breakthroughs that have revolutionized the field of regenerative medicine and anti-aging treatments.
Next-Generation Cytokines Technology
Breakthrough the level of stem cells and enter the third generation of stem cell technology - the field of cytokines. First patented technology to reach a level lower than stem cells, avoiding cell rejection risk.
Zero Age Bottleneck
Breakthrough the age bottleneck and enter the era of final cell repair for zero-year-old babies. Safe and free of rejection, no longer limited to autologous cell culture between 30-50 years old.
Long-Term Activity Storage
Breakthrough the time limit of cell product activity. Can be stored at room temperature and maintain long-acting activity for 2 years with TGA approval for commercial use.
Research Pipeline
Purecell's research pipeline showcases their commitment to advancing regenerative medicine through innovative technologies and rigorous clinical trials.
Current UCF Cytokines Projects
Two groundbreaking projects that demonstrate the commercial viability and therapeutic potential of UCF cytokines technology.
UCF Cytokines Anti-Aging Injection
$54.8 million USDThe world's first cytokines anti-aging solution: reactivate stem cells, target organ repair, fully surpass the anti-aging effect of stem cells.
UCF Knee Joint Repair
$36 million USDThe world's first UCF cytokines knee joint repair molding product. More efficient, safer, and more convenient than stem cell technology.